Supersaturation Potential of Ordered Mesoporous Silica Delivery

Jul 9, 2018 - Tahnee J. Dening and Lynne S. Taylor* ... Mugheirbi, Mosquera-Giraldo, Borca, Slipchenko, and Taylor. 0 (0),. Abstract: ... Frank, and M...
0 downloads 0 Views 637KB Size
Subscriber access provided by UNIV OF DURHAM

Article

Supersaturation Potential of Ordered Mesoporous Silica Delivery Systems. Part 1: Dissolution Performance and Drug Membrane Transport Rates Tahnee Jade Dening, and Lynne S. Taylor Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.8b00488 • Publication Date (Web): 09 Jul 2018 Downloaded from http://pubs.acs.org on July 11, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 44 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

Supersaturation Potential of Ordered Mesoporous Silica Delivery Systems. Part 1: Dissolution Performance and Drug Membrane Transport Rates

Tahnee J. Dening1, Lynne S. Taylor1,*

1. Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States

*To whom correspondence should be addressed. Email: [email protected]; Fax: +1 (765) 494-6545; Tel: +1 (765) 496-6614.

ACS Paragon Plus Environment

Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1

Abstract

2

Ordered mesoporous silica materials have shown great potential as oral drug delivery systems for

3

poorly soluble drugs. However, the ability of these delivery systems to generate drug

4

supersaturation has not been widely investigated, and the recently noted phenomenon of

5

incomplete drug release is not well understood. Therefore, the aim of this study was to

6

comprehensively evaluate the release of hydrophobic drug molecules into solution from ordered

7

mesoporous silica, focusing on the extent and duration of drug supersaturation. The dissolution

8

and supersaturation behavior of ritonavir, following loading into mesoporous SBA-15 silica

9

particles, was investigated by undertaking simple in vitro dissolution studies in phosphate buffer

10

pH 6.8 and fasted state simulated intestinal fluid, as well as membrane flux studies using a side-

11

by-side diffusion cell apparatus. It was found that supersaturated ritonavir solutions were

12

generated from ritonavir-loaded mesoporous SBA-15 particles, however, drug release was

13

always incomplete, even under sink conditions. In addition, the percentage drug release was

14

observed to decrease significantly as the theoretical supersaturation ratio and dose of ritonavir-

15

loaded SBA-15 formulation increased. The data obtained suggest an equilibrium exists between

16

drug adsorbed to the SBA-15 silica surface and free drug present in solution. The findings

17

described herein are highly significant in aiding our understanding of ordered mesoporous silica

18

as a supersaturating drug delivery system for bioavailability enhancement.

19

Keywords. mesoporous; silica; SBA-15; hydrophobic drug; supersaturation; dissolution;

20

incomplete release.

ACS Paragon Plus Environment

Page 2 of 44

Page 3 of 44 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

21

Introduction

22

Owing to the advent of combinatorial chemistry and high throughput screening, low aqueous

23

solubility and high hydrophobicity are common characteristics of up to 90% of drug candidates

24

currently under development.1-2 As a result, there is significant interest in the use of enabling

25

formulation strategies to enhance drug solubility and boost drug absorption from the

26

gastrointestinal tract. Such strategies can typically be classified into two broad categories.

27

Solubilizing formulations enhance the crystalline solubility of the drug by using additives such

28

as surfactants, cosolvents or complexing agents.3 In contrast, supersaturating formulations

29

generate drug concentrations that are higher than the crystalline solubility.4 In this case, the

30

chemical potential or thermodynamic activity of the solute exceeds that of the solute in a

31

saturated solution, leading to the significant advantage of increased flux across the

32

gastrointestinal membrane.5 Examples of supersaturating formulations include some lipid-based

33

formulations,4, 6 salts7-8 and amorphous solid dispersions.9-10

34

Amorphous solid dispersions, consisting of amorphous drug combined with a polymeric

35

crystallization inhibitor, have attracted substantial attention owing to their ability to generate and

36

maintain a supersaturated drug solution upon dissolution.11 Amorphous drug exists in a higher

37

free energy state in comparison to the crystalline solid, owing to disruption of the crystal lattice.

38

Spontaneous recrystallization to a more stable form is thermodynamically favored, and thus a

39

polymer is typically used to impede crystallization from both the solid formulation and in

40

solution following dissolution.12 Several amorphous solid dispersion products have been

41

commercialized,13 and significant research efforts are ongoing to better understand these

42

complex delivery systems.14-17

ACS Paragon Plus Environment

Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 44

43

As an alternative to polymer-based amorphous solid dispersions, mesoporous materials are being

44

increasingly utilized to stabilize and deliver amorphous drugs via the oral route.18 The adsorption

45

of drug molecules onto porous and nonporous silica has been described since the 1970s,19-21 and

46

in 2001, ordered mesoporous silica (OMS) was first proposed as a vehicle for controlled drug

47

delivery.22 OMS materials possess a regular arrangement of uniform pores with diameters of 2-

48

30 nm, and have large specific surface areas (SSA), often in the range of 500-1000 m2/g.23 The

49

large SSA of OMS materials leads to a high surface free energy, thus adsorption of drug

50

molecules onto the silica surface allows the system to progress to a lower free energy state.12, 24

51

As a result, adsorbed drug molecules exist in an amorphous and thermodynamically stable state,

52

due to an overall decrease in the Gibbs free energy of the system.12,

53

further enhanced due to a size-constraint effect on drug nucleation and crystal growth. Provided

54

the mesopore diameter is small enough, spatial constraints prevent clusters of amorphous drug

55

molecules reaching the critical nucleus size, and thus spontaneous drug crystallization within the

56

mesopores is inhibited.12, 24

57

Several studies have been undertaken to characterize the dissolution and release behavior of

58

various hydrophobic drug molecules from OMS materials. Many of these studies have

59

demonstrated the ability of OMS to enhance the rate and extent of drug dissolution in

60

comparison to crystalline drug,27-31 however, few studies have examined the performance of

61

OMS delivery systems under supersaturating (i.e. non-sink) conditions.32-34 Mellaerts et al.

62

investigated the release of itraconazole from mesoporous SBA-15 silica under supersaturating

63

conditions in simulated gastric fluid, and observed that the concentration of itraconazole in

64

solution was maintained well above the crystalline solubility for the duration of the experiment

65

(60 min).32 However, despite a supersaturated solution being generated, the percentage release of

ACS Paragon Plus Environment

25-26

Physical stability is

Page 5 of 44 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

66

itraconazole plateaued at approximately 55% when the drug load in SBA-15 was 20% w/w. The

67

authors suggested a dynamic adsorption equilibrium had been reached, however, no further

68

investigations were undertaken to explore this phenomenon. Significantly, such incomplete drug

69

release from OMS is often a feature during dissolution under both sink27,

70

supersaturating conditions.31-34, 38-41

71

To better understand the potential of OMS materials as supersaturating oral drug delivery

72

systems, this study aimed to comprehensively characterize the ability of mesoporous SBA-15

73

silica to generate and maintain drug supersaturation in solution. Ritonavir was selected as the

74

model compound, owing to its slow crystallization tendency from solution, thereby allowing

75

supersaturation to be easily characterized in vitro. The hypothesis to be tested was that

76

mesoporous SBA-15 silica can generate and maintain a supersaturated solution of ritonavir

77

during dissolution under non-sink conditions, with the maximum achievable supersaturation

78

being dictated by the amorphous solubility of ritonavir. Experimentally, the hypothesis was

79

tested by monitoring the ritonavir concentration in solution during dissolution studies with

80

ritonavir-loaded SBA-15 particles, and by conducting diffusion experiments, whereby drug flux

81

across an artificial membrane was assessed and compared against the flux generated by neat

82

amorphous ritonavir.

83

Materials and Methods

84

Materials

85

Ritonavir and lopinavir were purchased from ChemShuttle (Hayward, CA). SBA-15 material

86

with pore diameter 7.1 nm, pore volume 0.80 cm3/g and SSA 586 m2/g was supplied by Glantreo

87

(Cork, Ireland). Hydroxypropyl methylcellulose (HPMC) (Pharmacoat® 606) was obtained from

ACS Paragon Plus Environment

29, 31, 35-37

and

Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

88

Shin-Etsu Chemical Co. Ltd. (Tokyo, Japan). Fasted state simulated intestinal fluid (FaSSIF)

89

powder was obtained from Biorelevant.com (London, United Kingdom). Polytetrafluoroethylene

90

(PTFE) syringe filters with pore size 1.0 µm and diameter 4 mm were supplied by Tisch

91

Scientific (North Bend, OH). Buffer salts and analytical grade solvents were obtained from

92

Fisher Chemical (Fair Lawn, NJ). Regenerated cellulose membrane with a molecular weight cut-

93

off (MWCO) of 6-8 kDa was acquired from Spectrum Laboratories Inc. (Rancho Dominguez,

94

CA). The aqueous media used in all experiments was 50 mM sodium phosphate buffer pH 6.8

95

with and without 5 µg/mL HPMC. HPMC was used to inhibit ritonavir crystallization during

96

experiments where necessary.

97

Methods

98

Crystalline and Amorphous Solubility Measurements

99

The crystalline solubility of ritonavir in 50 mM phosphate buffer pH 6.8 was determined by

100

equilibrating an excess of crystalline ritonavir (polymorph form II) in 15 mL of medium using an

101

agitating water bath (Dubnoff metallic shaking incubator, PGC Scientific, Palm Desert, CA) set

102

at 37 °C for 48 h. The undissolved crystalline material was separated from solution by

103

centrifugation at 21,100 × g for 30 min (37 °C) using a Sorvall™ Legend™ Micro 21R

104

Microcentrifuge (ThermoFisher Scientific, Waltham, MA). The supernatant was diluted with

105

acetonitrile and analyzed via high performance liquid chromatography (HPLC) using the method

106

described below.

107

The amorphous solubility of ritonavir was also determined using centrifugation. A methanolic

108

solution of drug concentration 10 mg/mL was prepared, and 75 µL was added to 15 mL of 50

109

mM phosphate buffer pH 6.8 at 37 °C under stirring at 300 rpm. To ensure nucleation and

ACS Paragon Plus Environment

Page 6 of 44

Page 7 of 44 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

110

crystallization of ritonavir did not occur during the experiment, the amorphous solubility was

111

also determined in the presence of 5 µg/mL HPMC. The turbid solutions were immediately

112

centrifuged at 21,100 × g for 40 min (37 °C) to pellet the drug-rich phase. The supernatant was

113

diluted with acetonitrile and analyzed via HPLC as described below.

114

The crystalline and amorphous solubility of ritonavir was also measured in FaSSIF, using the

115

methods described above.

116

Estimation of Ritonavir Molecular Dimensions

117

The molecular dimensions of the ritonavir molecule were measured using Mercury CSD 3.10.1

118

software (Cambridge Crystallographic Data Centre, Cambridge, United Kingdom) and the single

119

crystal structure with a reference code of YIGPIO. The “measure distance” tool was used to

120

determine the distance between the atoms furthest apart in approximately orthogonal directions.

121

The surface area for adsorption was then estimated from the product of the two longest

122

dimensions.

123

Preparation of Ritonavir-Loaded SBA-15 Formulations

124

Ritonavir was loaded into SBA-15 material using a solvent incipient wetness impregnation

125

method.32 A concentrated methanolic solution of the drug (25 mg in 400 µL) was added

126

dropwise to 75 mg SBA-15 to achieve the desired drug loading, and intensively mixed with a

127

spatula. The solvent was subsequently removed from the sample by drying in an oven at 40 °C

128

for 24 h, followed by 48 h under reduced pressure at ambient temperature. The drug content was

129

confirmed using a solvent extraction technique, whereby a known quantity of sample was

130

dispersed in methanol with the aid of ultrasonication (Cole Parmer Ultrasonic Cleaner Model

ACS Paragon Plus Environment

Molecular Pharmaceutics 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

131

8892, Vernon Hills, IL) for 30 min. Samples were then centrifuged at 21,100 × g for 10 min and

132

the supernatant was diluted with acetonitrile prior to HPLC analysis.

133

X-Ray Powder Diffraction (XRPD) Analysis

134

Drug crystallinity in the ritonavir-loaded SBA-15 formulations was analyzed by measuring the

135

X-ray powder diffraction pattern using a Rigaku Smartlab™ diffractometer (Tokyo, Japan).

136

Samples were scanned over the range 5 to 40° 2θ at a scanning rate of 4°/min and step size of

137

0.02°. The voltage and current were set at 40 kV and 44 mA, respectively.

138

Dissolution Experiments

139

To evaluate the supersaturation potential of SBA-15, dissolution experiments were performed in

140

50 mM phosphate buffer pH 6.8 media. The buffered solution (75 mL) was equilibrated in a

141

jacketed-vessel maintained at 37 °C under stirring at 300 rpm. The ritonavir-loaded SBA-15

142

formulation was dosed at the amorphous solubility of ritonavir, to generate a maximum

143

supersaturation ratio (S) of 7.8. This required 9.4 mg sample to be added to the medium. The

144

formulation was also dosed at half the amorphous solubility of ritonavir (i.e. S of 3.9), which

145

required 4.7 mg sample per dissolution experiment. Dissolution was monitored over 120 min,

146

and 0.7 mL sample aliquots were withdrawn at fixed time points. Samples were centrifuged at

147

21,100 × g for 10 min (37 °C) and the supernatant was diluted with acetonitrile and analyzed via

148

HPLC.

149

For the sequential dilution dissolution study, 50 mL buffered solution was equilibrated as

150

described above. Approximately 6.3 mg sample was added to the dissolution medium to generate

151

a supersaturated solution of ritonavir (S of 7.8), and 0.5 mL sample aliquots were withdrawn

152

every 15 min over a 180 min period. Every 30 min, fresh phosphate buffer (pre-equilibrated to

ACS Paragon Plus Environment

Page 8 of 44

Page 9 of 44 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

153

37 °C) was added to dilute the medium, such that the theoretical maximum concentration of

154

ritonavir in solution was decreased in increments and was approximately equal to the equilibrium

155

crystalline solubility of ritonavir during the final 30 min. The maximum supersaturation ratio

156

was decreased by dilution as follows: S=7.8 at 0 min; S=3.9 at 30 min; S=2.6 at 60 min; S=1.9 at

157

90 min; S=1.6 at 120 min; S=1.3 at 150 min; S=1 at 180 min. Samples were prepared for HPLC

158

analysis as described above.

159

For dissolution experiments conducted at total drug concentrations above the amorphous

160

solubility of ritonavir, samples were prepared for analysis using a filtration method. This

161

technique allows for the quantification of both free drug in solution and drug-rich nanodroplets

162

formed when the amorphous solubility is exceeded; the drug-rich nanodroplets formed by

163

ritonavir were estimated using dynamic light scattering (Zetasizer Nano-ZS, Malvern, United

164

Kingdom) to have a Z-average diameter of 740 ± 45 nm (PDI 0.23 ± 0.12) when the

165

concentration of ritonavir in solution was 56 µg/mL. Previous studies have also confirmed the

166

formation of ritonavir nanodroplets of size